[1] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版).中华临床感染病杂志,2012,5:321-327.
[2] 叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击.中华肝脏病杂志,2009,17:638-640.
[3] 杨瑞华,李芹,林恢,刘政芳,齐艳平.HBV相关慢加急性肝衰竭患者外周血T细胞亚群、NK细胞的变化及其与预后的关系.中国中西医结合消化杂志 ,2014,22:595-597.
[4] Mohd Talha, Noor,Piyush, Manoria. Immune Dysfunction in Cirrhosis.. J Clin Transl Hepatol,2017,5:50-58.
[5] Pei F,Guan X.Thymosin alPha 1 treatment for Patients with sePsis.ExPert OPin Biol Ther 2018;18:71- 76.
[6] Camerini R,Garaci E.Historical review of thymosin alPha 1 in infectious diseases.Exp Opin Biol Ther,2015,15 SuPPl 1:S117-127.
[7] Li C,Bo L,LiuQ,et al.Thymosin alPha1 based immunomodulatory theraPy for sePsis a systemati creview and meta-analysis.Int J Infect Dis,2015,33:90-96.
[8] 降钙素原急诊临床应用专家共识组.降钙素原(PCT)急诊临床应用的专家共识.中华急诊医学杂志,2012,21:944-951.
[9] 韩英,崔丽娜,郭冠亚.慢加急性肝衰竭的免疫治疗.临床肝胆杂志,2017,33:1677-1682.
[10] Shiomi A,Usui T,Ishikawa Y,et al.GM-CSFbutnotIL-17 iscritical for the develoPment of severe interstitial lungdisease inSKGmice.J Immunol,2014,193:849-859. |
